argenx Announces Annual General Meeting of Shareholders on May 27, 2025
argenx SE (Euronext & Nasdaq: ARGX) has announced its Annual General Meeting of shareholders, scheduled for May 27, 2025, at 13:00 CET. The meeting will take place at the Hilton Amsterdam Schiphol.
The agenda includes standard items such as the discussion and adoption of 2024 annual accounts, advisory vote on the 2024 remuneration report, discharge of directors, and authorization for the Board to issue shares and handle pre-emptive rights. Key proposals include the re-appointment of Anthony Rosenberg as a non-executive director and the adoption of a new remuneration policy.
Shareholders are encouraged to use voting by electronic proxy. All meeting documents and the company's 2024 annual report are available on argenx's website and www.abnamro.com/evoting.
argenx SE (Euronext & Nasdaq: ARGX) ha annunciato la sua Assemblea Generale Annuale degli azionisti, programmata per il 27 maggio 2025, alle 13:00 CET. L'incontro si terrà presso l'Hilton Amsterdam Schiphol.
L'ordine del giorno include elementi standard come la discussione e l'adozione dei bilanci annuali 2024, il voto consultivo sul rapporto di remunerazione 2024, la liberazione dei direttori e l'autorizzazione per il Consiglio di amministrazione a emettere azioni e gestire i diritti di prelazione. Le proposte chiave includono il rinnovo dell'incarico di Anthony Rosenberg come direttore non esecutivo e l'adozione di una nuova politica di remunerazione.
Si incoraggiano gli azionisti a utilizzare il voto tramite delega elettronica. Tutti i documenti dell'incontro e il rapporto annuale 2024 dell'azienda sono disponibili sul sito web di argenx e su www.abnamro.com/evoting.
argenx SE (Euronext & Nasdaq: ARGX) ha anunciado su Asamblea General Anual de accionistas, programada para el 27 de mayo de 2025, a las 13:00 CET. La reunión tendrá lugar en el Hilton Amsterdam Schiphol.
El orden del día incluye puntos estándar como la discusión y aprobación de las cuentas anuales 2024, el voto consultivo sobre el informe de remuneración 2024, la descarga de directores y la autorización para que la Junta emita acciones y maneje los derechos de preferencia. Las propuestas clave incluyen la reelección de Anthony Rosenberg como director no ejecutivo y la adopción de una nueva política de remuneración.
Se anima a los accionistas a utilizar el voto por poder electrónico. Todos los documentos de la reunión y el informe anual 2024 de la empresa están disponibles en el sitio web de argenx y en www.abnamro.com/evoting.
argenx SE (Euronext & Nasdaq: ARGX)는 2025년 5월 27일 13:00 CET에 예정된 주주 총회를 발표했습니다. 회의는 힐튼 암스테르담 스키폴에서 열릴 예정입니다.
의제에는 2024년 연간 재무제표의 논의 및 채택, 2024년 보수 보고서에 대한 자문 투표, 이사 면책 및 이사회가 주식을 발행하고 우선권을 처리할 수 있는 권한 부여와 같은 표준 항목이 포함됩니다. 주요 제안에는 앤서니 로젠버그를 비상임 이사로 재임명하는 것과 새로운 보수 정책의 채택이 포함됩니다.
주주들은 전자 위임장을 통한 투표를 권장합니다. 모든 회의 문서와 회사의 2024년 연례 보고서는 argenx의 웹사이트와 www.abnamro.com/evoting에서 확인할 수 있습니다.
argenx SE (Euronext & Nasdaq: ARGX) a annoncé sa Réunion Générale Annuelle des actionnaires, prévue pour le 27 mai 2025 à 13h00 CET. La réunion se tiendra à l'Hilton Amsterdam Schiphol.
L'ordre du jour comprend des points standards tels que la discussion et l'adoption des comptes annuels 2024, un vote consultatif sur le rapport de rémunération 2024, la décharge des administrateurs et l'autorisation pour le Conseil d'émettre des actions et de gérer les droits de préférence. Les propositions clés incluent la réélection d'Anthony Rosenberg en tant qu'administrateur non exécutif et l'adoption d'une nouvelle politique de rémunération.
Les actionnaires sont encouragés à voter par procuration électronique. Tous les documents de la réunion et le rapport annuel 2024 de l'entreprise sont disponibles sur le site web d'argenx et sur www.abnamro.com/evoting.
argenx SE (Euronext & Nasdaq: ARGX) hat seine Jahreshauptversammlung der Aktionäre angekündigt, die für den 27. Mai 2025 um 13:00 Uhr CET geplant ist. Die Versammlung findet im Hilton Amsterdam Schiphol statt.
Die Tagesordnung umfasst Standardpunkte wie die Diskussion und Genehmigung der Jahresabschlüsse 2024, eine beratende Abstimmung über den Vergütungsbericht 2024, die Entlastung der Direktoren und die Ermächtigung des Vorstands zur Ausgabe von Aktien und zur Handhabung von Bezugsrechten. Wichtige Vorschläge beinhalten die Wiederbestellung von Anthony Rosenberg als nicht-executive Director und die Annahme einer neuen Vergütungspolitik.
Aktionäre werden ermutigt, die Abstimmung per elektronischer Vollmacht zu nutzen. Alle Versammlungsunterlagen und der Jahresbericht 2024 des Unternehmens sind auf der Website von argenx und auf www.abnamro.com/evoting verfügbar.
- None.
- None.
April 11, 2025, 10:01 PM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.
The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
The company’s annual report for the financial year ended December 31, 2024 is now available on its website www.argenx.com/investors/financial-reports.
Agenda
In addition to recurrent items on the agenda, such as the discussion and adoption of the 2024 annual accounts, an advisory vote on the company’s 2024 remuneration report, the discharge of the directors for their duties performed in 2024 and the authorization of the Board of Directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, it is proposed to re-appoint Anthony Rosenberg as a non-executive director to the Board of Directors and to adopt a new remuneration policy.
The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
When and where is argenx (ARGX) holding its 2025 Annual General Meeting?
What are the key agenda items for ARGX's 2025 Annual General Meeting?
How can shareholders access ARGX's 2024 annual report and meeting documents?
What voting options are available for ARGX shareholders for the 2025 AGM?
